Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
Moore CM, Robertson NL, Jichi F, Damola A, Ambler G, Giganti F, Ridout AJ, Bott SR, Winkler M, Ahmed HU, Arya M, Mitra AV, McCartan N, Freeman A, Jameson C, Castro R, Gambarota G, Whitcher BJ, Allen C, Kirkham A, Emberton M. Moore CM, et al. Among authors: castro r. J Urol. 2017 Apr;197(4):1006-1013. doi: 10.1016/j.juro.2016.11.090. Epub 2016 Nov 19. J Urol. 2017. PMID: 27871928 Free article. Clinical Trial.
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Gambarota G, Whitcher B, Castro R, Emberton M, Allen C, Kirkham A. Giganti F, et al. Among authors: castro r. Eur Radiol. 2017 Nov;27(11):4767-4774. doi: 10.1007/s00330-017-4858-0. Epub 2017 May 18. Eur Radiol. 2017. PMID: 28523355 Free PMC article. Clinical Trial.
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R. Roehrborn CG, et al. Among authors: castro r. BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9. BJU Int. 2014. PMID: 24127818 Clinical Trial.
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group. Andriole GL, et al. Among authors: castro r. J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074214 Clinical Trial.
Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R. Schröder F, et al. Among authors: castro r. Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12. Eur Urol. 2013. PMID: 23176897 Free article. Clinical Trial.
2,141 results